BODENSTEDT MATTHIAS (Chief Financial Officer) received a stock award from MOONLAKE IMMUNOTHERAPEUTICS
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/9/2026ACC: 0001213900-26-002907
Officer· Chief Financial Officer
Since Apr 2022
+354.30K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
354.30K acquired
Non-Derivative Transactions1
Class A ordinary shares, par value $0.0001 per share
Direct
Shares
+354.30K
Price / share
—
Trade value
—
% of position
38.4%
1/7/2026
922.01K→1.28M
Total
Net shares
+354.30K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per share Direct | 1/7/2026 | A · Award | +354.30K | — | — | 38.4% | 922.01K | 1.28M |
| Total | +354.30K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported